MedTrace Logo

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

NCT00398216 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 903

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.

Conditions

Interventions

DRUG

DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States
  • Canada
  • Denmark
  • Hungary
  • Latvia
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398216 on ClinicalTrials.gov